Spironolactone Liquid Formulation Stability and Dosing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current spironolactone formulations lack stability and uniformity, leading to potential microbial contamination, dosing errors, and reduced patient compliance due to the need for compounding, which affects both pharmacists and patients, especially in severe heart failure and pediatric cases where tablet administration is not feasible.
Innovation Solution
A stable, ready-to-use liquid formulation of spironolactone is developed, comprising spironolactone, xanthan gum, an anti-foaming agent, preservative, dispersing agent, sweetening agent, flavoring agent, and a buffer, which maintains pH within a specific range, enhancing bioavailability and reducing sedimentation issues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If spironolactone is compounded from tablets or powder, then a liquid formulation can be prepared for patients who cannot take tablets, but the formulation lacks stability and is prone to microbial contamination
Solution Approach 1:
The patent applies parameter changes by optimizing the pH of the vehicle to be between 3.0 and 6.0 and controlling the alcohol content between 5% and 20%. These specific parameter ranges create an environment that maintains spironolactone stability while preventing microbial growth, resolving the contradiction between formulation adaptability and stability.
Solution Approach 2:
The patent uses a composite vehicle system combining water, alcohol, and preservative agents (such as benzoic acid or propionic acid). This composite formulation provides both the liquid delivery capability needed for patient compliance and the chemical stability required to prevent degradation and microbial contamination.
2Ease of operation
If spironolactone is compounded in pharmacy, then liquid formulation can be prepared, but dosing errors and compounding variability occur
Solution Approach 1:
The patent applies preliminary action by pre-calculating and pre-formulating exact spironolactone concentrations in the liquid vehicle during manufacturing. This ensures that each dose contains the precise amount of drug intended, eliminating dosing errors that occur during pharmacy compounding while maintaining administration flexibility.
Solution Approach 2:
The patent replaces the mechanical compounding process (grinding, mixing, suspending) with a chemically stable solution formulation. This substitution eliminates variability inherent in mechanical compounding operations while providing a ready-to-administer liquid dosage form with consistent, accurate dosing.
3Ease of manufacture
If simple syrup vehicle with preservative is used, then compounding is possible, but stability is limited and shelf life is reduced
Solution Approach 1:
The patent extends shelf life by changing the vehicle composition parameters: using a broader alcohol range (5-20%) rather than fixed 10%, adjusting pH to 3.0-6.0 range, and selecting from multiple preservative options. These parameter optimizations maintain compounding feasibility while achieving stable formulations with extended shelf life of at least 6 months.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation provides improved bioavailability, increased stability, and enhanced patient compliance by ensuring uniform dosing with minimal shaking requirements, reducing the likelihood of dosing errors and maintaining spironolactone content over extended storage periods.
Implementation Method 1
xanthan gum... reducing sedimentation issues
Implementation Method 2
a buffer, which maintains pH within a specific range
Implementation Method 3
dispersing agent, ensuring uniform dosing
Data Source
AI summary
Disclosed herein is a stable, ready-to-use liquid formulation comprising spironolactone and its method of use.